We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
Read MoreHide Full Article
On Sep 25, we issued an updated research report on STERIS plc (STE - Free Report) — a manufacturer and marketer of infection prevention, decontamination, microbial reduction along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #3 (Hold).
Over the last three months, this Ohio-based company has been trading above the broader industry. The stock has gained 4.7% in contrast to a 0.2% slip of the broader industry during the period.
We are impressed with the company’s persistently strong organic growth performance across all segments. Also, gross and operating margins expanded year over year. Recently, the company made a couple of organizational changes to serve customers in a better way. We expect this move to enhance the company’s cost structure as well. Further, growth in free cash flow reserve is indicative of the company’s strong cash balance.
However, we note that the government and insurance companies’ consistent efforts to curb healthcare costs have been putting pressure on the stock for quite some time. We are also concerned about the current customer consolidation scenario, which will continue to affect the company, unless checked immediately. The competitive landscape and weak cost reduction initiatives are other overhangs.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained roughly 4.2% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has surged around 36.4% over the last year.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has rallied around 10.3% over the last year.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
On Sep 25, we issued an updated research report on STERIS plc (STE - Free Report) — a manufacturer and marketer of infection prevention, decontamination, microbial reduction along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #3 (Hold).
Over the last three months, this Ohio-based company has been trading above the broader industry. The stock has gained 4.7% in contrast to a 0.2% slip of the broader industry during the period.
We are impressed with the company’s persistently strong organic growth performance across all segments. Also, gross and operating margins expanded year over year. Recently, the company made a couple of organizational changes to serve customers in a better way. We expect this move to enhance the company’s cost structure as well. Further, growth in free cash flow reserve is indicative of the company’s strong cash balance.
STERIS PLC Price
STERIS PLC Price | STERIS PLC Quote
However, we note that the government and insurance companies’ consistent efforts to curb healthcare costs have been putting pressure on the stock for quite some time. We are also concerned about the current customer consolidation scenario, which will continue to affect the company, unless checked immediately. The competitive landscape and weak cost reduction initiatives are other overhangs.
Key Picks
Some better-ranked medical stocks are Chemed Corporation (CHE - Free Report) , IDEXX Laboratories, Inc (IDXX - Free Report) and Amedisys, Inc. (AMED - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Chemed has a long-term expected earnings growth rate of 10%. The stock has gained roughly 4.2% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has surged around 36.4% over the last year.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has rallied around 10.3% over the last year.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>